ARK Genomic Revolution ETF
ARKG ThematicUpdated: Apr 6, 2026, 12:07 UTC
Key Metrics
Top 10 Holdings
| Holding | Ticker | Weight | Bar |
|---|---|---|---|
| CRISPR Therapeutics AG | CRSP | 9.96% | |
| Tempus AI Inc Class A common stock | TEM | 8.26% | |
| Twist Bioscience Corp | TWST | 7.88% | |
| 10x Genomics Inc Ordinary Shares - Class A | TXG | 6.06% | |
| Personalis Inc | PSNL | 6.03% | |
| Beam Therapeutics Inc | BEAM | 5.12% | |
| Illumina Inc | ILMN | 4.27% | |
| Guardant Health Inc | GH | 4.16% | |
| Natera Inc | NTRA | 3.93% | |
| Recursion Pharmaceuticals Inc Class A | RXRX | 3.73% |
Sector Allocation
About This ETF
The ARK Genomic Revolution ETF (ARKG) is a Thematic ETF with an expense ratio (TER) of 0.75% and $1.3B in assets under management., with its largest holdings being CRISPR Therapeutics AG, Tempus AI Inc Class A common stock, Twist Bioscience Corp. Year-to-date, ARKG has returned -6.24%.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Where can I buy ARKG?
Compare the best brokers for ETF savings plans — low fees, trusted providers, fully regulated.